Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02928224
Recruitment Status : Active, not recruiting
First Posted : October 10, 2016
Results First Posted : July 14, 2020
Last Update Posted : February 17, 2021
Sponsor:
Collaborators:
Merck KGaA, Darmstadt, Germany
Pierre Fabre Medicament
Ono Pharmaceutical Co. Ltd
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib + binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.

Condition or disease Intervention/treatment Phase
BRAF V600E-mutant Metastatic Colorectal Cancer Drug: Encorafenib Drug: Binimetinib Drug: Cetuximab Drug: Irinotecan Drug: Folinic Acid Drug: 5-Fluorouracil Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 702 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Actual Study Start Date : October 13, 2016
Actual Primary Completion Date : February 11, 2019
Estimated Study Completion Date : May 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Safety Lead-in, Triplet Arm
Encorafenib + binimetinib + cetuximab.
Drug: Encorafenib
Orally, once daily.

Drug: Binimetinib
Orally, twice daily.

Drug: Cetuximab
Standard of care.

Experimental: Doublet Arm
Encorafenib + cetuximab.
Drug: Encorafenib
Orally, once daily.

Drug: Cetuximab
Standard of care.

Active Comparator: Control Arm
Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Drug: Cetuximab
Standard of care.

Drug: Irinotecan
Standard of care.

Drug: Folinic Acid
Standard of care.
Other Name: FA

Drug: 5-Fluorouracil
Standard of care.
Other Name: 5-FU




Primary Outcome Measures :
  1. (Safety Lead-in) Number of Participants With Dose-limiting Toxicities (DLTs) [ Time Frame: Cycle 1 (up to 28 days) ]
  2. (Safety Lead-in) Number of Participants With Adverse Events (AEs) [ Time Frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) ]
    Refer to AE/SAE section for additional data that were measured and analyzed.

  3. (Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) [ Time Frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) ]
  4. (Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  5. (Phase 3) Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]

Secondary Outcome Measures :
  1. (Safety Lead-in) Response Rate (ORR) by Investigator [ Time Frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) ]
  2. (Safety Lead-in) Response Rate (ORR) by BICR [ Time Frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) ]
    ORR per RECIST, v1.1, defined as the number of patients achieving an overall best response of CR or partial response (PR) divided by the total number of patients

  3. (Safety Lead-in) Duration of Response (DOR) by Investigator [ Time Frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) ]
  4. (Safety Lead-in) Duration of Response (DOR) by BICR [ Time Frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) ]
    DOR defined as the time from first radiographic evidence of response to the earliest documented disease progression or death due to underlying disease

  5. (Safety Lead-in) Time to Response by Investigator [ Time Frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) ]
    Time to response defined as the time from first dose to first radiographic evidence of response

  6. (Safety Lead-in) Time to Response by BICR [ Time Frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) ]
    Time to response defined as the time from first dose to first radiographic evidence of response

  7. (Safety Lead-in) Progression-free Survival (PFS) by Investigator [ Time Frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) ]
  8. (Safety Lead-in) Progression-free Survival (PFS) by BICR [ Time Frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) ]
    PFS defined as the time from first dose to the earliest documented disease progression or death due to any cause

  9. (Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  10. (Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  11. (Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per BICR [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  12. (Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  13. (Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per BICR [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  14. (Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  15. (Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  16. (Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  17. Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  18. (Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  19. (Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  20. Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  21. Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  22. (Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  23. (Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  24. (Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  25. (Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  26. (Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  27. (Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  28. (Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  29. (Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  30. (Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  31. (Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  32. (Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  33. (Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
  34. (Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Patients (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
    The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.

  35. (Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
    FACT-C is a well-characterized and commonly used questionnaire that belongs to the Functional Assessment of Chronic Illness Therapy Measurement System (FACIT). The FACT-G (G for general) questionnaire (27 questions) constitutes the core of all subscales and is applicable to all tumor types. The FACT-C questionnaire contains 9 additional questions on symptoms specific to CRC, 2 of which are only answered by patients with ostomy appliances. These 9 CRC-specific questions are categorized as "additional concerns" on the questionnaire and constitute the "colorectal cancer subscale" score. The patient self-reports his/her QoL for the previous 7 days. The overall score is calculated across all items and a higher score reflects better quality of life (QoL). The table summarizes the functional well-being subscale, the individual questions are linearly scaled and combined to form the functional well-being subscale score, which ranges from 0-28 (higher is better QoL).

  36. (Phase 3) Change From Baseline in the EuroQol-5D-5L (EQ-5D-5L) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
    The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the patient and ranges from 0 to 100 (higher is better quality health).

  37. (Phase 3) Change From Baseline in the Patient Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet [ Time Frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ]
    The PGIC is a measure of patients' perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other patient reported outcome (PROs). For this assessment, patients answered the following question: "Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse."

  38. (Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Cetuximab [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  39. (Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Encorafenib [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  40. (Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Binimetinib [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  41. (Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Metabolite of Binimetinib (AR00426032) [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  42. (Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  43. (Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  44. (Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  45. (Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032) [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  46. (Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  47. (Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  48. (Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  49. (Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032) [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  50. (Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Binimetinib [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  51. (Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Encorafenib [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  52. (Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Cetuximab [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  53. (Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for a Metabolite of Binimetinib [ Time Frame: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 ]
  54. (Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib [ Time Frame: 2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2. ]
    The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.

  55. (Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib [ Time Frame: 2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2. ]
    The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.

  56. (Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab [ Time Frame: 2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2. ]
    The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Age ≥ 18 years at time of informed consent
  • Histologically- or cytologically-confirmed CRC that is metastatic
  • Presence of BRAFV600E in tumor tissue as previously determined by a local assay at any time prior to Screening or by the central laboratory
  • Progression of disease after 1 or 2 prior regimens in the metastatic setting
  • Evidence of measurable or evaluable non-measurable disease per RECIST, v1.1
  • Adequate bone marrow, cardiac, kidney and liver function
  • Able to take oral medications
  • Female patients are either postmenopausal for at least 1 year, are surgically sterile for at least 6 weeks, or must agree to take appropriate precautions to avoid pregnancy from screening through follow-up if of childbearing potential
  • Males must agree to take appropriate precautions to avoid fathering a child from screening through follow-up

Key Exclusion Criteria:

  • Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab, panitumumab or other epidermal growth factor receptor (EGFR) inhibitors
  • Prior irinotecan hypersensitivity or toxicity that would suggest an inability to tolerate irinotecan 180 mg/m2 every 2 weeks
  • Symptomatic brain metastasis or leptomeningeal disease
  • History or current evidence of retinal vein occlusion or current risk factors for retinal vein occlusion (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes)
  • Known history of acute or chronic pancreatitis
  • History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤12 months prior to randomization
  • Uncontrolled blood pressure despite medical treatment
  • Impaired GI function or disease that may significantly alter the absorption of encorafenib or binimetinib (e.g., ulcerative diseases, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption)
  • Concurrent or previous other malignancy within 5 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy
  • History of thromboembolic or cerebrovascular events ≤ 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli
  • Concurrent neuromuscular disorder that is associated with the potential of elevated creatine (phosphor)kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)
  • Residual common terminology criteria for adverse events (CTCAE) ≥ Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathy
  • Known history of HIV infection
  • Active hepatitis B or hepatitis C infection
  • Known history of Gilbert's syndrome
  • Known contraindication to receive cetuximab or irinotecan at the planned doses

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02928224


Locations
Hide Hide 428 study locations
Layout table for location information
United States, Arizona
Mayo Clinic Hospital
Phoenix, Arizona, United States, 85054
Mayo Clinic
Phoenix, Arizona, United States, 85054
Mayo Clinic
Scottsdale, Arizona, United States, 85259
United States, California
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California, United States, 91010
Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc.
Fountain Valley, California, United States, 92708
Keck Hospital of USC - Norris Healthcare Center (HC3)
Los Angeles, California, United States, 90033
Keck Hospital of USC
Los Angeles, California, United States, 90033
LAC+USC Medical Center
Los Angeles, California, United States, 90033
Norris Healthcare Center 3 (HC3)
Los Angeles, California, United States, 90033
USC Eye Institute
Los Angeles, California, United States, 90033
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States, 92663
Harvard Eye Associates
Orange, California, United States, 92868
United States, Colorado
Rocky Mountain Lions Eye Institute
Aurora, Colorado, United States, 80045
University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado, United States, 80045
University of Colorado Denver CTO (CTRC)
Aurora, Colorado, United States, 80045
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, Colorado, United States, 80045
University of Colorado Hospital Inpatient Pavillion'
Aurora, Colorado, United States, 80045
United States, Connecticut
Smilow Cancer Hospital at Yale - New Haven
New Haven, Connecticut, United States, 06510
Temple Medical Center
New Haven, Connecticut, United States, 06510
Yale University, Yale Cancer Center
New Haven, Connecticut, United States, 06520
Smilow Cancer Hospital Care Center at North Haven
North Haven, Connecticut, United States, 06473
United States, Florida
The Lennar Foundation Medical Center
Coral Gables, Florida, United States, 33146
Broward Health Medical Center
Fort Lauderdale, Florida, United States, 33316
Dr. Clayton Berger (opthalmology)
Fort Lauderdale, Florida, United States, 33316
Mehmet F. Hepgur, MD - Broward Health Medical Center
Fort Lauderdale, Florida, United States, 33316
Mayo Clinic Florida
Jacksonville, Florida, United States, 32224
Bascon Palmer Eye Institue
Miami, Florida, United States, 33136
Sylvester Comprehensive Cancer Center/UMHC
Miami, Florida, United States, 33136
Sylvester at Kendall
Miami, Florida, United States, 33176
United States, Illinois
Illinois CancerCare- Bloomington
Bloomington, Illinois, United States, 61704
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
Illinois CancerCare- Galesburg
Galesburg, Illinois, United States, 61401
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
New Lenox, Illinois, United States, 60451
The University of Chicago Medicine Center for Advanced Care Orland Park
Orland Park, Illinois, United States, 60462
Illinois CancerCare- Ottawa
Ottawa, Illinois, United States, 61350
Illinois Cancer Care, PC
Peoria, Illinois, United States, 61615
Illinois Eye Center
Peoria, Illinois, United States, 61615
Carle Cancer Center
Urbana, Illinois, United States, 61801
United States, Indiana
Indiana University Health Hospital
Indianapolis, Indiana, United States, 46202
Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
Investigational Drug Services IUHSCC
Indianapolis, Indiana, United States, 46202
Sidney &Lois Eskenazi Hospital
Indianapolis, Indiana, United States, 46202
IU Health Springmill
Indianapolis, Indiana, United States, 46290
Baptist Health Floyd Cancer Center
New Albany, Indiana, United States, 47150
United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242
United States, Kansas
The University of Kansas Clinical Research Center
Fairway, Kansas, United States, 66205
The University of Kansas Hospital
Kansas City, Kansas, United States, 66160
KU Eye
Prairie Village, Kansas, United States, 66208
The University of Kansas Cancer Center and Medical Pavilion
Westwood, Kansas, United States, 66205
The University of Kansas Cancer Center, Investigational Drug Services
Westwood, Kansas, United States, 66205
United States, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana, United States, 70121
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21287
The Investigational Drug Pharmacy (IDS) in the Sidney Kimmel Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21287
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Ophthalmic Consultants of Boston Inc
Boston, Massachusetts, United States, 02114
Brigham & Women's Hospital
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute (DFCI)
Boston, Massachusetts, United States, 02215
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Missouri
Siteman Cancer Center - West County
Creve Coeur, Missouri, United States, 63141
SSM Health Saint Louis University Hospital
Saint Louis, Missouri, United States, 63104
Barnes Jewish Hospital
Saint Louis, Missouri, United States, 63110
Saint Louis University
Saint Louis, Missouri, United States, 63110
SSM Health Saint Louis University Hospital
Saint Louis, Missouri, United States, 63110
Washington University Infusion Center Pharmacy
Saint Louis, Missouri, United States, 63110
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
Siteman Cancer Center - South County
Saint Louis, Missouri, United States, 63129
Siteman Cancer Center - St Peters
Saint Peters, Missouri, United States, 63376
United States, New York
Memorial Sloan Kettering: Commack
Commack, New York, United States, 11725
Memorial Sloan Kettering: Rockefeller Outpatient Pavilion
New York, New York, United States, 10022
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Ohio
Gabrail Cancer Center Research
Canton, Ohio, United States, 44718
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, United States, 44195
United States, Oregon
Casey Eye Institute-South Waterfront
Portland, Oregon, United States, 97239
OHSU Center for Health and Healing
Portland, Oregon, United States, 97239
OHSU Research Pharmacy Services
Portland, Oregon, United States, 97239
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, Tennessee
Henry-Joyce Cancer Clinic
Nashville, Tennessee, United States, 37232
Vanderbilt Eye Institute
Nashville, Tennessee, United States, 37232
United States, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030-4009
Scott & White Clinic - Temple Pavilion
Temple, Texas, United States, 76504
Scott & White Medical Center - Temple
Temple, Texas, United States, 76508
United States, Washington
Medical Oncology Associates, PS DBA Summit Cancer Centers
Spokane Valley, Washington, United States, 99216
Spokane Eye Clinic
Spokane, Washington, United States, 99204
Inland Imaging, LLC Holy Family Hospital
Spokane, Washington, United States, 99208
Medical Oncology Associates, PS DBA Summit Cancer Centers
Spokane, Washington, United States, 99208
Providence Holy Family Nuclear Medicine
Spokane, Washington, United States, 99208
United States, Wisconsin
University of Wisconsin Clinical Science Center
Madison, Wisconsin, United States, 53792
Argentina
CLINICA PERGAMINO S.A. (Centro de Investigacion Pergamino S.A.)
Pergamino, Buenos Aires, Argentina, 2700
Centro Medico INFINITO
Santa Rosa, LA Pampa, Argentina, L6300EAN
Centro Medico CAIPO (Centro para la Atención del paciente Oncológico)
San Miguel de Tucumán, Tucumán, Argentina, T4000GTB
Clinica Universitaria Reina Fabiola
Cordoba, Argentina, X5004FHP
Centro Oncologico Riojano Integral - CORI
La Rioja, Argentina, 5300
Australia, NEW South Wales (nsw)
St Vincent's Clinic
Darlinghurst, NEW South Wales (nsw), Australia, 2010
St Vincent's Hospital Sydney
Darlinghurst, NEW South Wales (nsw), Australia, 2010
Marsden Eye Specialists
Parramatta, NEW South Wales (nsw), Australia, 2150
Newcastle Eye Centre
Sydney, NEW South Wales (nsw), Australia, 2300
Australia, Queensland
Mater Misericordiae Limited
South Brisbane, Queensland, Australia, 4101
Australia, South Australia
Central Adelaide Local Health Network Inc. operating as Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Flinders Medical Centre
Bedford Park, South Australia, Australia, 5042
Central Adelaide Local Health Network Inc. operating as The Queen Elizabeth Hospital
Woodville South, South Australia, Australia, 5011
Australia, Victoria
Monash Health Translation Precinct - Monash Health
Clayton, Victoria, Australia, 3168
Austin Health
Heidelberg, Victoria, Australia, 3084
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia, 3000
Austria
Klinikum Wels - Grieskirchen GmbH, Abteilung fuer Innere Medizin IV
Wels, Oberoesterreich, Austria, 4600
Klinikum Wels-Grieskirchen GmbH, Abteilung fuer Augenheilkunde und Optometrie
Wels, Oberoesterreich, Austria, 4600
Klinikum Wels-Grieskirchen GmbH, Abteilung fuer Innere Medizin II
Wels, Oberoesterreich, Austria, 4600
Klinikum Wels-Grieskirchen GmbH, Apotheke
Wels, Oberoesterreich, Austria, 4600
Klinikum Wels-Grieskirchen GmbH, Institut fuer Nuklearmedizin
Wels, Oberoesterreich, Austria, 4600
Klinikum Wels-Grieskirchen GmbH, Institut fuer Radiologie I
Wels, Oberoesterreich, Austria, 4600
DZU, Diagnose Zentrum Urania GmbH
Wien, Austria, 1010
AKH Wien
Wien, Austria, 1090
Medizinische Universitaet Wien/AKH Wien
Wien, Austria, 1090
Medizinische Universität Wien/AKH Wien
Wien, Austria, 1090
Belgium
Centre Hospitalier de l'Ardenne - Site de Libramont
Libramont-Chevigny, Luxembourg, Belgium, 6800
AZ Sint-Jan Brugge - Oostende AV - Campus Sint-Jan - Oncology
Brugge, WEST Vlaanderen, Belgium, 8000
Imelda Ziekenhuis
Bonheiden, Belgium, 2820
Grand Hopital de Charleroi (GHdC)
Charleroi, Belgium, 6000
UZ Antwerpen
Edegem, Belgium, 2650
AZ Maria Middelares
Gent, Belgium, 9000
University Hospital Gasthuisberg (UZ Leuven)
Leuven, Belgium, 3000
Centre Hospitalier Universitaire (CHU) de Liege
Liege, Belgium, 4000
CHC Saint Joseph
Liege, Belgium, 4000
AZ Delta Roeselaere-Menen
Roeselaere, Belgium, 8800
Centre Hospitalier Regional (CHR) - Verviers
Verviers, Belgium, 4800
Brazil
Hospital do Hlho
Salvador, Bahia, Brazil, 41820-020
CENOB - Centro de Oncologia da Bahia SS Ltda / Oncovida
Salvador, Bahia, Brazil, 41820-021
CEMES Centro Medico Especializado em Oftalmologia
Cachoeiro de Itapemirim, ES, Brazil, 29300-045
Centro de Pesquisas Clínicas em Oncologia
Cachoeiro de Itapemirim, ES, Brazil, 29308-014
Hospital Evangelico de Cachoeiro de Itapemirim
Cachoeiro de Itapemirim, ES, Brazil, 29308-055
Instituto Vizibelli
Belo Horizonte, Minas Gerais, Brazil, 30110-921
CENANTRON - Centro Avancado de Tratamento Oncologic
Belo Horizonte, Minas Gerais, Brazil, 30130-090
Fundação Universidade de Caxias do Sul
Caxias do Sul, RS, Brazil, 95070-560
Daniel Lubisco Pandolfi
Lajeado, RS, Brazil, 95900-000
Sociedade Beneficencia e Cardade de Lajeado/Hospital Bruno Born
Lajeado, RS, Brazil, 95900-000
Sociedade Beneficencia e Cardade de Lajeado/Hospital Bruno Born
Lajeado, RS, Brazil, 95900-010
Associacao Hospitalar Beneficente Sao Vicente de Paulo / Hospital Sao Vicente de Paulo
Passo Fundo, RS, Brazil, 99010-080
Consultorio Medico de Oftalmologia - Dr. Ricardo Tres
Passo Fundo, RS, Brazil, 99010-080
Hospital Sao Vicente de Paulo
Passo Fundo, RS, Brazil, 99010-090
Thiago Vernetti Ferreira
Pelotas, RS, Brazil, 96010-140
Leandro Becker
Pelotas, RS, Brazil, 96015-280
Fernanda Mendes
Pelotas, RS, Brazil, 96020-080
UPCO - Unidade de Pesquisas Clinicas em Oncologia
Pelotas, RS, Brazil, 96020-080
Fernanda Lauermann
Pelotas, RS, Brazil, 96020-260
Diogo Duarte Torre
Porto Alegre, RS, Brazil, 90020-013
Farmacia Central da Irmandade da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, RS, Brazil, 90020-090
Irmandade da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, RS, Brazil, 90020-090
Nucleo de Novos Tratamentos em Cancer
Porto Alegre, RS, Brazil, 90050-170
Centro de Pesquisa Clínica de Oncologia e Hematologia - Hospital Mãe de Deus/AESC
Porto Alegre, RS, Brazil, 90110-270
Clinica de Oftalmologia Lavinsky
Porto Alegre, RS, Brazil, 90470-340
Hospital Mãe de Deus
Porto Alegre, RS, Brazil, 90880-480
Clinica Toller
Barretos, SAO Paulo, Brazil, 14780-110
Olhos Centro Diagnostico e Laser LTDA
Barretos, SAO Paulo, Brazil, 14780-300
Fundacao Pio XII
Barretos, SAO Paulo, Brazil, 14784-400
Giuliano Santos Borges - ME / Clinica de Neoplasias Litoral - Centro de Novos Tratamentos Itajai
Itajai, SC, Brazil, 88301-220
FUNDAÇÃO DO ABC - Faculdade de Medicina do ABC
Santo Andre, SP, Brazil, 09060-650
FUNDAÇÃO DO ABC - Faculdade de Medicina do ABC
Santo Andre, SP, Brazil, 09060-870
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
Sao Jose do Rio Preto, SP, Brazil, 15090-000
CEPOS - Centro de Estudos e Pesquisas Oncologicas de Sorocaba
Sorocaba, SP, Brazil, 18030-075
Instituto de Oncologia de Sorocaba "Dr. Gilson Delgado"
Sorocaba, SP, Brazil, 18030-200
Karen Miyuki Kubokawa Shorer
Sorocaba, SP, Brazil, 18040-425
Oftalmologia Diagnostica de Sorocaba (ODS)
Sorocaba, SP, Brazil, 18047-620
Instituto de Ensino e Pesquisa São Lucas
São Paulo, Brazil, 01236-030
Instituto de Ensino e Pesquisa São Lucas - Pharmacy
São Paulo, Brazil, 01242-020
Hospital Leforte
São Paulo, Brazil, 01507-000
IPEPO - Instituto da Visao
São Paulo, Brazil, 04038-020
Canada, British Columbia
Eye Care Centre, Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 3N9
BC Cancer, Vancouver Center
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada, K1H 8L6
Sunnybrook Research Institute
Toronto, Ontario, Canada, M4N 3M5
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5
Canada, Quebec
Centre integre universitaire de sante et de services sociaux de l'Ouest-de-l'Ile-de-Montreal
Montreal, Quebec, Canada, H3T 1M5
Chile
Instituto Clinico Oncologico del Sur (ICOS)
Temuco, Region DE LA Araucania, Chile, 4810469
Hospital Clinico Vina Del Mar
Vina del Mar, V Region Valparaiso, Chile, 2520612
Czechia
Ocni ordinace Oftalpro s.r.o.
Brno, Czechia, 603 00
Masarykuv onkologicky ustav
Brno, Czechia, 656 53
Fakultni nemocnice Hradec Kralove
Hradec Kralove, Czechia, 500 05
Fingerlanduv ustav patologie
Hradec Kralove, Czechia, 500 05
I. interni kardioangiologicka klinika
Hradec Kralove, Czechia, 500 05
Klinika nemoci koznich a pohlavnich
Hradec Kralove, Czechia, 500 05
Nemocnicni lekarna - Usek klinickych studii
Hradec Kralove, Czechia, 500 05
Ocni klinika
Hradec Kralove, Czechia, 500 05
Radiologicka klinika
Hradec Kralove, Czechia, 500 05
Fakultni nemocnice Olomouc, I. interni klinika - kardiologicka
Olomouc, Czechia, 779 00
Fakultni nemocnice Olomouc, Lekarna
Olomouc, Czechia, 779 00
Fakultni nemocnice Olomouc
Olomouc, Czechia, 779 00
Denmark
Odense University Hospital (OUH)
Odense C, Denmark, DK-5000
France
Hopital Jean Minjoz
Besancon Cedex, France, 25030
CHU Morvan
BREST Cedex, France, 29609
Centre Ophtalmologique - Pole Vision - Clinique Val d'Ouest
Ecully, France, 69130
Centre Leon Berard
Lyon Cedex 08, France, 69373
ICM Val d'Aurelle
Montpellier Cedex 5, France, 34298
CHU HOTEL-Dieu
Nantes Cedex, France, 44093
Centre hospitalier national d'ophtalmologie des Quinze-Vingts
Paris Cedex 12, France, 75571
Centre Hospitalier National d'Opthalmologie des Quinze-Vingts (CHNO des XV-XX)
Paris Cedex 12, France, 75571
Hopital Georges Pompidou
Paris, France, 75015
CHU Robert Debre
Reims Cedex, France, 51092
SCM Centre d'ophtalmologie
Saint Jeand De Vedas, France, 34430
CHU Toulouse-Institut Inuversitaire du Cancer Toulouse
Toulouse Cedex 9, France, 31059
CHU Toulouse-Rangueil
Toulouse Cedex 9, France, 31059
CHU Toulouse - Purpan, hopital Pierre-Paul Riquet
Toulouse, France, 31057
Gustave Roussy
Villejuif Cedex, France, 94805
Germany
Universitaetsklinikum Tuebingen
Tuebingen, Baden-wuerttemberg, Germany, 72076
Universitaetsklinikum Ulm
Ulm, Baden-wuerttemberg, Germany, 89081
Augenklinik der Universitaet Muenchen
Muenchen, Bayern, Germany, 80336
LMU Klinikum der Universitaet Muenchen, Campus Grosshadern
Muenchen, Bayern, Germany, 81377
Augenarzt-Gemeinschaftspraxis Dr.med.Andreas Kind & Dr.med. Ute Kariger-Schweigert
Falkensee, Brandenburg, Germany, 14612
Medizinische Hochschule Hannover (MHH)
Hannover, Niedersachsen, Germany, 30625
Medizinische Hochschule Hannover
Hannover, Niedersachsen, Germany, 30625
Kliniken Essen Mitte / Knappschaftskrankenhaus
Essen, Nordrhein-westfalen, Germany, 35136
Praxis fuer Augenheilkunde Dr. Edmund Meyer-Schwickerath
Essen, Nordrhein-westfalen, Germany, 45131
Kliniken Essen-Mitte
Essen, Nordrhein-westfalen, Germany, 45136
Universitaetsklinikum Essen (AoeR), Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum
Essen, Nordrhein-westfalen, Germany, 45147
Universitaetsklinikum Essen; Diagnostischeu. Interventionelle Radiologie u. Neuroradiologie
Essen, Nordrhein-westfalen, Germany, 45147
Universitaetsklinikum Essen; Nuklearmedizin
Essen, Nordrhein-westfalen, Germany, 45147
Universitaetsklinikum Essen; Zentralapotheke
Essen, Nordrhein-westfalen, Germany, 45147
Evang. Krankenhaus Essen - Werden; Klinik fuer Augenheilkunde
Essen, Nordrhein-westfalen, Germany, 45239
Kliniken Essen Mitte / Knappschaftskrankenhaus
Essen, Nordrhein-westfalen, Germany, 45276
Augentagesklinik Maria-Hilf Krankenhaus
Moenchengladbach, Nordrhein-westfalen, Germany, 41063
Kliniken Maria Hilf GmbH - Franziskuskrankenhaus
Moenchengladbach, Nordrhein-westfalen, Germany, 41063
Kliniken Maria Hilf GmbH; Klinik fuer Radiologie
Moenchengladbach, Nordrhein-westfalen, Germany, 41063
Lukaskrankenhaus Neuss; Zentrale Apotheke
Neuss, Nordrhein-westfalen, Germany, 41464
Institut f. Pathologie - Ruhr-Universitaet Bochum, Prof. Dr. med. Andrea Tannapfel
Bochum, North Rhine Westfalia, Germany, 44789
Augenarzt Praxis Dr. med. Petra Huelsmann
Worms, Rheinland-pfalz, Germany, 67547
Gemeinschaftspraxis fuer Radiologie und Nuklearmedizin, Standort Worms
Worms, Rheinland-pfalz, Germany, 67547
Martin Apotheke
Worms, Rheinland-pfalz, Germany, 67547
Onkologische Schwerpunktpraxis Worms
Worms, Rheinland-pfalz, Germany, 67547
Praxisgemeinschaft Kruse + Hofstaetter
Worms, Rheinland-pfalz, Germany, 67547
Evangelisches Waldkrankenhaus Spandau
Berlin, Germany, 13589
Universitaetsklinikum Carl Gustav Carus der Technischen Universitaet Dresden
Dresden, Germany, 01307
Universitaetsklinikum Hamburg Eppendorf, Klinik fuer Augenheilkunde
Hamburg, Germany, 20246
Facharztzentrum Eppendorf
Hamburg, Germany, 20249
Universitaetsklinikum Hamburg Eppendorf, Zentrum fuer Radiologie und Endoskopie
Hamburg, Germany, 20251
ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld
Hamburg, Germany, 22045
HKS Kardiologische Praxis am Israelitischen Krankenhaus
Hamburg, Germany, 22297
Radiologie im Israelitischen Krankenhaus
Hamburg, Germany, 22297
Hungary
Zala Megyei Szent Rafael Korhaz - Onkologiai Osztaly
Zalaegerszeg, Zala, Hungary, H-8900
Szent Margit Kórház
Budapest, Hungary, 1032
Magyar Honvedseg Egeszsegugyi Kozpont
Budapest, Hungary, 1062
Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet
Budapest, Hungary, 1097
Uzsoki Utcai Korhaz
Budapest, Hungary, 1145
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hungary, 4032
Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar
Pecs, Hungary, 7624
Pecsi Tudomanyegyetem Klinikai Kozpont
Pecs, Hungary, 7624
Israel
Tel Aviv Sourasky Medical Center - Oncology
Tel-Aviv, NAP, Israel, 6423906
The Barzilai Medical Center - Oncology Institute
Ashkelon, Israel, 7830604
Soroka University Medical Center
Be'er-Sheva, Israel, 8410101
MOR Institute
Bnei Brak, Israel, 5126413
Ein-Karem Department of Medical Imaging of Hadassah Medical Organization, Hadassah Medical Center,
Jerusalem, Israel, 9112001
Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem
Jerusalem, Israel, 9112001
Pharmacy of Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem
Jerusalem, Israel, 9112001
Mt. Scopus Department of Medical Imaging of Hadassah Medical Organization,
Jerusalem, Israel, 91240
Imaging Department of Meir Medical Center
Kfar Saba, Israel, 4428164
Meir Medical Center
Kfar Saba, Israel, 4428164
Pharmacy of Meir Medical Center
Kfar Saba, Israel, 4428164
Pharmacy of Rabin Medical Center, Beilinson Hospital
Petah Tikva, Israel, 4941492
Rabin Medical Center, Beilinson Hospital
Petah Tikva, Israel, 4941492
The Chaim Sheba Medical Center
Tel-Hashomer, Israel, 5262100
Italy
Ospedali Riuniti Umberto I
Torrette Di Ancona, Ancona, Italy, 60020
ASST Bergamo Ovest, Ospedale Treviglio Caravaggio di Trevigl
Treviglio, Bergamo, Italy, 24047
Farmacia - ASST Papa Giovanni XXIII
Bergamo, BG, Italy, 24127
Oculistica, ASST Papa Giovanni XXIII
Bergamo, BG, Italy, 24127
Oncologia, ASST Papa Giovanni XXIII
Bergamo, BG, Italy, 24127
Clinica di Oncologia Medica AOU di Cagliari Presidio Duilio Casula Monserrato
Monserrato, Cagliari, Italy, 09042
Farmacia AOU di Cagliari Presidio Duilio Casula Monserrato
Monserrato, Cagliari, Italy, 09042
Radiologia AOU di Cagliari Presidio Duilio Casula Monserrato
Monserrato, Cagliari, Italy, 09042
Oculistica - ASST Cremona, Ospedale di Cremona
Cremona, CR, Italy, 26100
SC Farmacia Aziendale - ASST Cremona, Ospedale di Cremona
Cremona, CR, Italy, 26100
SC Oncologia - ASST Cremona, Ospedale di Cremona
Cremona, CR, Italy, 26100
U.O. Oculistica, Istituto Clinico HUMANITAS
Rozzano, Milano, Italy, 20089
U.O. di Oncologia ed Ematologia, Istituto Clinico HUMANITAS
Rozzano (MI), Milan, Italy, 20089
IRCCS Ospedale San Raffaele - U.O. di Medicina Oncologica
Milano, MI, Italy, 20132
Servizio di Farmacia - IRCCS Ospedale San Raffaele
Milano, MI, Italy, 20132
S.C. Radiologia diagnostica e interventistica - Fondazione IRCCS Istituto Nazionale dei Tumori
Milano, MI, Italy, 20133
SC Farmacia - Fondazione IRCCS Istituto Nazionale dei Tumori
Milano, MI, Italy, 20133
SC Oncologia Medica 1, SS Oncologia Medica Gastroenterologica
Milano, MI, Italy, 20133
Cardiologia per i pazienti oncologici - Istituto Oncologico Veneto I.R.C.C.S
Padova, PD, Italy, 35128
Clinica Oculistica - Azienda Ospedaliera di Padova
Padova, PD, Italy, 35128
Servizio Farmacia - Istituto Oncologico Veneto I.R.C.C.S
Padova, PD, Italy, 35128
U.O. Oncologia Medica 1 - Istituto Oncologico Veneto I.R.C.C.S
Padova, PD, Italy, 35128
Policlinico S.Orsola Malpighi, AOU di Bologna - Oncologia Medica
Bologna, Italy, 40138
Divisione Anatomia Patologica Presidio San Giovanni di Dio
Cagliari, Italy, 09124
Oculistica AOU di Cagliari Presidio San Giovanni di Dio
Cagliari, Italy, 09124
AOU Careggi - Oncologia Medica 1
Firenze, Italy, 50134
SC oncologia Medica I - Azienda Ospedaliero Universitaria Careggi
Firenze, Italy, 50134
Radiologia
Milano, Italy, 20141
Servizio Farmacia Ospedaliera
Milano, Italy, 20141
Unita di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini
Milano, Italy, 20141
Grande Ospedale Metropolitano Niguarda
Milano, Italy, 20162
Dipartimento Interaziendale Farmaceutico - AOU Policlinico di Modena
Modena, Italy, 41124
SC di Oftalmologia - AOU Policlinico di Modena
Modena, Italy, 41124
SC di Radiologia, Dipartimento Interaziendale integrato Diagnostica per Immagini
Modena, Italy, 41124
SSD Day Hospital Oncologico - Dipartimento ad attivita integrata di Oncologia, Ematologia
Modena, Italy, 41124
AOU Universita degli Studi della Campania L. Vanvitelli - DAI di Medicina Interna e Specialistica
Napoli, Italy, 80131
AOU Universita degli Studi della Campania L. Vanvitelli - U. Ma.Ca.
Napoli, Italy, 80131
AOU Universita degli Studi della Campania L. Vanvitelli
Napoli, Italy, 80131
AOU Universita degli Studi della Campania L. Vanvitelli
Napoli, Italy, 80138
UO Oculistica - AOU Pisana, Stabilimento Ospedaliero di Cisanello
Pisa, Italy, 56124
SOD Radiodiagnostica 3 - AOU Pisana, Stabilimento Ospedaliero di Santa Chiara
Pisa, Italy, 56126
UO Farmaceutica, Gestione del Farmaco - AOU Pisana, Stabilimento Ospedaliero di Santa Chiara
Pisa, Italy, 56126
UO Oncologia Medica 2 - AOU Pisana, Stabilimento Ospedaliero di Santa Chiara
Pisa, Italy, 56126
U.O.C. Farmacia Clinica - Fondazione PTV Policlinico Tor Vergata
Roma, Italy, 00133
U.O.S.D. Oncologia Medica, Dipartimento di Medicina - Fondazione PTV Policlinico Tor Vergata
Roma, Italy, 00133
U.O.S.D. Patologie Retiniche - Fondazione PTV Policlinico Tor Vergata
Roma, Italy, 00133
Japan
Aichi Cancer Center Hospital
Nagoya, Aichi, Japan, 464-8681
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan, 277-8577
Hokkaido University Hospital
Sapporo, Hokkaido, Japan, 060-8648
Kanazawa University Hospital
Kanazawa, Ishikawa, Japan, 920-8641
St. Marianna University School of Medicine Hospital
Kawasaki, Kanagawa, Japan, 216-8511
Tsukahara Eye Clinic
Yokohama, Kanagawa, Japan, 241-0821
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan, 241-8515
Osaka University Hospital Laboratory for Clinical Investigation
Suita, Osaka, Japan, 565-0871
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan, 104-0045
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan, 811-1395
Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers
Fukuoka, Japan, 815-8588
National Hospital Organization Osaka National Hospital
Osaka, Japan, 540-0006
Korea, Republic of
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
Ajou University Hospital
Suwon, Gyeonggi-do, Korea, Republic of, 16499
Hallym University Sacred Heart Hospital
Anyang, Gyeonggido, Korea, Republic of, 14068
Chonnam National University Hwasun Hospital
Hwasun-gun, Jeollanam-do, Korea, Republic of, 58128
Korea University Guro Hospital
Seoul, Seoul Teugbyeolsi, Korea, Republic of, 08308
Dong-A University Hospital
Busan, Korea, Republic of, 49201
Gachon University Gil Medical Center
Incheon, Korea, Republic of, 21565
Korea University Anam Hospital
Seoul, Korea, Republic of, 02841
Seoul National University Hospital
Seoul, Korea, Republic of, 03080
Severance Hospital, Yonsei University Health System
Seoul, Korea, Republic of, 03722
Asan Medical Center
Seoul, Korea, Republic of, 05505
Samsung Medical Center
Seoul, Korea, Republic of, 06351
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, Korea, Republic of, 06591
Mexico
Superare Centro de Infusion S.A. de C.V.
Delegacion Cuauhtemoc, Ciudad DE Mexico, Mexico, 06760
Consultorio dentro de la Torre Medica Dalinde (Oncologia Medica)
Ciudad de Mexico, Cuauhtemoc, Mexico
Netherlands
Rijnstate Hospital Arnhem
Arnhem, Gelderland, Netherlands, 6815 AD
Rijnstate Hospital Velp
Velp, Gelderland, Netherlands, 6883 AZ
Maastricht University Medical Center (MUMC)
Maastricht, Limburg, Netherlands, 6229HX
The Netherlands Cancer Institute
Amsterdam, Noord-holland, Netherlands, 1066 CX
Onze Lieve Vrouwen Gasthuis
Amsterdam, Noord-holland, Netherlands, 1091 AC
Haga Ziekenhuis
Den Haag, Zuid-holland, Netherlands, 2545 AA
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands, 3584 CX
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands, 3584CX
Norway
Colosseum Øyelegesenter C/O LB Holdings AS
Lommedalen, Norway, 1350
Colosseum Øyelegesenter C/O LB Holdings AS
Oslo, Norway, 0369
Oslo universitetssykehus, Radiumhospitalet
Oslo, Norway, 0379
Sykehusapoteket Oslo, Radiumhospitalet
Oslo, Norway, 0379
Poland
Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza
Brzozow, Poland, 36-200
Wojewodzki Szpital Zespolony, Oddzial Onkologiczny
Elblag, Poland, 82-300
Szpital Specjalistyczny im. L. Rydygiera w Krakowie Sp.z.o.o.
Krakow, Poland, 31-826
Europejskie Centrum Zdrowia Otwock, Szpital im. F. Chopina
Otwock, Poland, 05-400
NZOZ Centrum Medyczne HCP
Poznan, Poland, 61-485
NZOZ Przychodnia Specjalistyczna GUTMED
Poznan, Poland, 61495
Centrum Medyczne MAVIT Sp. z o.o.
Warszawa, Poland, 01-673
MAGODENT Sp. z o.o. Szpital Elblaska
Warszawa, Poland, 01-748
Magodent Sp. z o.o., Przychodnia Specjalistyczna i Rehabilitacja, Poradnia Okulistyczna
Warszawa, Poland, 02-524
MAGODENT Sp. z o.o. Szpital Onkologiczny, Oddzial Onkologii Klinicznej i Chemioterapii
Warszawa, Poland, 03-291
Magodent Sp. z o.o., Szpital Onkologiczno-Kardiologiczny, Dzial Farmacji Szpitalnej
Warszawa, Poland, 04-125
Russian Federation
Regional Budgetary Healthcare Institution Kursk Regional Clinical
Kursk, Kursk Region, Russian Federation, 305524
Evimed Llc
Chelyabinsk, Russian Federation, 454048
Federal State Budget Institution "N.N. Blokhin Russian Cancer Research Center" of the
Moscow, Russian Federation, 115478
Federal State Budget Institution "N.N. Blokhin Russian Cancer Research Center"
Moscow, Russian Federation, 115478
A. Tsyb Medical Radiological Research Center - branch of the
Obninsk, Russian Federation, 249036
State Budgetary Educational Institution of Higher Professional Education First Saint Petersburg
Sankt-Petersburg, Russian Federation, 197022
Spain
Complejo Hospitalario de Jaen
Jaen, Andalucia, Spain, 23007
Sercosa - Clinica de las Nieves
Jaen, Andalucia, Spain, 23007
Hospital Universitario Son Espases
Palma de Mallorca, Baleares, Spain, 07010
Institut Catala d'Oncologia
L'Hospitalet de Llobregat, Barcelona, Spain, 08908
Hospital Universitari Parc Tauli
Sabadell, Barcelona, Spain, 08208
Hospital Universitario Reina Sofía
Cordoba, Cordona, Spain, 14004
Hospital Nuestra Señora del Rosario
Madrid, Madrid, Communidad Delaware, Spain, 28006
Hospital Universitari Sant Joan de Reus
Reus, Tarragona, Spain, 43204
Hospital del Mar
Barcelona, Spain, 08003
Clinica Corachan
Barcelona, Spain, 08017
Hospital Quiron Salud Barcelona
Barcelona, Spain, 08023
Cetir Centre Medic S.L.
Barcelona, Spain, 08029
Hospital Universitario Vall d'Hebron
Barcelona, Spain, 08035
Hospital Universitario de Burgos
Burgos, Spain, 09006
Consulta Dr. Juan Carlos Castillo Dominguez
Cordoba, Spain, 14008
Gabinete Radiologico Dr. Pita
Madrid, Spain, 28006
Hospital General Universitario Gregorio Maranon
Madrid, Spain, 28007
Hospital Universitario Ramón y Cajal
Madrid, Spain, 28034
Hospital Clinico San Carlos
Madrid, Spain, 28040
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain, 28040
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Hospital Universitario La Paz
Madrid, Spain, 28046
Hospital HM Universitario Sanchinarro
Madrid, Spain, 28050
Hospital Universitario Virgen del Rocio
Sevilla, Spain, 41013
Clinica Oftalvist
Valencia, Spain, 46004
Fundacion Instituto Valenciano de Oncologia
Valencia, Spain, 46009
Hospital Clinico Universitario de Valencia
Valencia, Spain, 46010
Hospital General Universitario de Valencia
Valencia, Spain, 46014
Hospital Quiron Salud Zaragoza
Zaragoza, Spain, 50006
Hospital Universitario Miguel Servet
Zaragoza, Spain, 50009
Taiwan
Changhua Christian Hospital
Changhua city, Changhua County, Taiwan, 500
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan, 807
China Medical University Hospital
Taichung, Taiwan, 40447
National Cheng Kung University Hospital
Tainan, Taiwan, 704
National Taiwan University Hospital
Taipei, Taiwan, 10002
Chang Gung Memorial Hospital, Linkou
Taoyuan, Taiwan, 333
Turkey
Ege University Medical Faculty
Izmir, Bornova, Turkey, 35100
Izmir Medical Park Hospital - Medical Oncology
Izmir, Izmir, Karsiyaka, Turkey, 35575
Istanbul Medeniyet University Göztepe Training and Research Hospital
Istanbul, Kadikoy, Turkey, 34722
Hacettepe University Medical Faculty
Ankara, Turkey, 06230
Uludag University Medical Faculty
Bursa, Turkey, 16059
Trakya Universitesi Tip Fakultesi
Edirne, Turkey, 22030
Inonu Universitesi Turgut Ozal Medical Center
Malatya, Turkey, 44280
Ukraine
Oftalmolohycheskyi tsentr "Vzghliad" MTs
Dnipropetrovsk, Dnipropetrovska Oblast', Ukraine, 41100
Oftalmolohycheskyi tsentr "Vzghliad" MTs
Dnipropetrovsk, Dnipropetrovska Oblast', Ukraine, 49027
Derzhavnyi zaklad, Dnipropetrovska medychna akademiia Ministerstva okhorony zdorovia Ukrainy
Dnipropetrovsk, Dnipropetrovska Oblast', Ukraine, 49102
Komumalnyi zaklad, Dnipropetrovska miska bahatoprofilna klinichna likarnia Nº4
Dnipropetrovsk, Dnipropetrovska Oblast', Ukraine, 49102
Kyivska klinichna likarnia na zaliznychnomu transporti No3 filii Tsentr okhorony zdorov'ia PAT
Kyiv, Kyivska Oblast', Ukraine, 02096
Natsionalnyi medychnyi universytet imeni O.O Bohomltsia, kafedra onkolohii
Kyiv, Kyivska Oblast', Ukraine, 02096
Natsionalnyi medychnyi universytet imeni O.O Bohomltsia, kafedra oftalmolohii
Kyiv, Kyivska Oblast, Ukraine, 01601
Oleksandrivska klinichna likarnia mista Kyieva
Kyiv, Kyivska Oblast, Ukraine, 01601
Kyivskyi miskyi klinichnyi onkotsentr
Kyiv, Kyivska Oblast, Ukraine, 03115
Vinnytskyi oblasnyi klinichnyi onkolohichnyi dyspanser, viddilennia khimioterapii
Vinnytsia, Vinnyts'ka Oblast', Ukraine, 21029
DVNZ "Uzhhorodskyi natsionalnyi universytet"
Uzhgorod, Zakarpats'ka Oblast', Ukraine, 88000
Tsentralna miska klinichna likarnia, Miskyi onkolohichnyi tsentr
Uzhgorod, Zakarpats'ka Oblast', Ukraine, 88000
DVNZ "Uzhhorodskyi natsionalnyi universytet"
Uzhhorod, Zakarpatska Oblast, Ukraine, 88000
TOV "Zakarpatskyi Tsentr Mikrokhirurhii Oka"
Uzhhorod, Zakarpatska Oblast, Ukraine, 88000
United Kingdom
NHS Grampian - Aberdeen Royal Infirmary
Aberdeen, Aberdeenshire Scotland, United Kingdom, AB25 2ZN
King Edward V11 Hospital
Windsor, Berkshire, United Kingdom, SL4 3DP
Beatson West of Scotland Cancer Centre
Glasglow, Glasglow City, Scotland, United Kingdom, G12 0YH
University Hospitals Birmingham NHS Foundation Trust Queen Elizabeth Hospital
Birmingham, WEST Midlands, United Kingdom, B15 2TH
Hammersmith Hospital, Imperial College Healthcare NHS Trust
London, United Kingdom, W12 0HS
Imperial College Healthcare NHS Trust, Hammersmith Hospital
London, United Kingdom, W12 0HS
Sarah Cannon Research Institute UK
London, United Kingdom, W1G 6AD
Imperial College Healthcare NHS Trust, Charing Cross Hospital
London, United Kingdom, W6 8RF
The Christie NHS Foundation Trust - Christie Hospital
Manchester, United Kingdom, M20 4BX
Sponsors and Collaborators
Pfizer
Merck KGaA, Darmstadt, Germany
Pierre Fabre Medicament
Ono Pharmaceutical Co. Ltd
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
  Study Documents (Full-Text)

Documents provided by Pfizer:
Study Protocol  [PDF] January 11, 2019
Statistical Analysis Plan  [PDF] January 28, 2019

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT02928224    
Other Study ID Numbers: ARRAY-818-302
BEACON CRC ( Other Identifier: Alias Study Number )
2015-005805-35 ( EudraCT Number )
C4221009 ( Other Identifier: Pfizer )
First Posted: October 10, 2016    Key Record Dates
Results First Posted: July 14, 2020
Last Update Posted: February 17, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Keywords provided by Pfizer:
Colorectal cancer
BRAF
BRAFV600E
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Leucovorin
Folic Acid
Fluorouracil
Irinotecan
Cetuximab
Levoleucovorin
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Antineoplastic Agents, Immunological
Antidotes
Protective Agents